CervoMed (CRVO) Q3 2026 earnings summary

Executive summary

• Neflamapimod is in development for DLB, nfvPPA, stroke recovery and ALS; supportive clinical and biomarker findings underpin the program, with 100mg BID dosing planned.

• Q3 net loss narrowed to $5.9M from $7.7M YoY as lower operating expenses more than offset the loss of grant revenue.

• September 30 cash, cash equivalents and marketable securities totaled $19.6M; management projected funding through Q3 2027 under its current plan, while financial statements cited substantial doubt and resources insufficient for 12 months from issuance.

• Priorities include securing a partner to advance DLB into Phase 3 and delivering clinical and biomarker readouts through 2027.

Financial highlights

• Q3 operating expenses were $6.1M, down 27% YoY; operating loss was $6.1M versus $8.0M, and net loss was $5.9M versus $7.7M.

• Q3 R&D expense was $3.7M versus $6.0M, mainly reflecting RewinD-LB completion and lower personnel and other costs; G&A was $2.4M versus $2.3M.

• Q3 grant revenue was zero versus $0.3M YoY; interest income was $0.2M versus $0.3M.

• 9M operating expenses were $20.9M, down 13%; net loss was $20.4M versus $18.9M as grant revenue fell to zero from $4.0M.

• Q3 net loss per share was $0.39 versus $0.84; 9M net loss per share was $1.77 versus $2.10.

Outlook and guidance

• Operating expenses may decline in Q4 as trial count and CMC activity decline; longer-term expenses are expected to rise with development and clinical activity.

• R&D spending is expected to increase as larger trials advance; G&A is expected to remain consistent short term while pursuing a strategic partnership, then rise with development and headcount.

• Cash at September 30, 2026 was expected to fund planned operating expenses and capital expenditures through Q3 2027 under the current operating plan; the financial statements state resources are insufficient for 12 months from issuance.

• Expected milestones: nfvPPA 24-week biomarkers at CTAD in November 2026, initial clinical and additional biomarker data in March 2027, and topline in Q2 2027; RESTORE topline by end-2026 and EXPERTS-ALS first dosing in Q1 2027.

• A planned Phase 3 DLB trial depends on available funding, including a strategic partnership.